Congenital malformations can be manifested as combinations of phenotypes that cooccur more often than expected by chance. In many such cases, it has proved difficult to identify a genetic cause. We sought the genetic cause of cardiac, vertebral, and renal defects, among others, in unrelated patients.
NAD Deficiency and Congenital Malformations
M ajor congenital malformations occur in at least 2% of human births. 1 There are relatively few identified causes. The origins of most malformations have been difficult to determine and probably involve genetic and environmental factors or gene-environment interaction. Although malformations frequently occur in isolation, they also occur in combination. 2 Vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities (VACTERL) together represent a nonrandom combination of congenital defects without a known cause. 3 Persons are considered to have the VACTERL association if they have any three of the above defects in the absence of a genetic cause. Our understanding of the genetic basis of congenital malformations is increasing, and many causes of isolated organ defects have been identified. Isolated heart defects are many and varied and are caused by pathogenic variation in approximately 60 genes. 4 Vertebral defects also show variability and are caused by mutations in genes associated with Notch signal transduction and somitogenesis. [5] [6] [7] [8] [9] [10] [11] However, the genetic causes of isolated cardiac or vertebral defects appear to have little relevance when these defects occur in combination. 12 To identify the genetic basis of multiple congenital malformations in individuals, we used genomic sequencing to identify potential diseasecausing mutations. We functionally assessed these mutations in vitro and defined their role in mouse embryogenesis.
Me thods

Study Participants
Patients with congenital vertebral and heart malformations from Families A, B, and C were identified by clinical geneticists at the Children's Hospital at Westmead and Liverpool Hospital (Australia). Family D underwent diagnostic sequencing at GeneDx (United States) and was subsequently identified through GeneMatcher 13 ( Fig. 1 ). Patients A, B, and C were part of a series of 13 families (3 consanguineous) with multiple congenital malformations, including vertebral and heart defects. Persons from all 13 families underwent sequencing.
Genomic and Genetic Analyses
All the families underwent whole-exome sequencing except for Family B, which underwent whole-genome sequencing. Methods of library Squares indicate male persons, circles female persons, triangles first-trimester deaths, solid symbols affected persons (patients), slashes deceased persons, and double horizontal lines consanguineous marriages. All persons in Families A, C, and D were evaluated by means of exome sequencing. All persons in Family B were evaluated by means of genome sequencing. In family D, two distinct variants in the KYNU gene were identified. Mutated alleles are depicted as "a" or "b" for HAAO and as "c," "d," or "e" for KYNU. The reference allele is depicted by a plus sign. 
II
T h e ne w e ngl a nd jou r na l o f m e dicine preparation, sequencing, variant detection, and resequencing are described in the Supplementary Appendix (available with the full text of this article at NEJM.org). Details of the enzyme assays, the quantification of metabolites in the kynurenine pathway, the generation of null alleles in mice, and analysis of mice embryos are also available in the Supplementary Appendix.
R esult s
Clinical Features of Affected Families
The clinical features of the study participants are summarized in Table 1 ; details are provided in the Results section and Table S1 in the Supplementary Appendix. The four families include one consanguineous family from Iraq (Family A), two consanguineous families from Lebanon (Families B and C), and a family from the United States without a history of consanguinity (Family D) (Fig. 1 ). There is no other history of congenital anomalies or intellectual disability in these families. The mother in Family B had insulinrequiring gestational diabetes. The mother in Family C had prepregnancy insulin-requiring diabetes, hypercholesterolemia, and a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 32. In addition to congenital malformations, postnatal growth and cognitive defects were evident. Patients A, B, and C had microcephaly. Patients A and D have extreme short stature. Patient A has moderate intellectual disability and behavioral issues at 12 years of age, and Patient D has speech delay at 3 years of age.
Pathogenic Variants in HAAO and KYNU
In the consanguineous families, variants were filtered according to a recessive inheritance model and a compound heterozygous inheritance model and on the assumption that a de novo mutation in the patient was a possibility. Additional filtering was used to select variants that were nonsynonymous, rare, and predicted to be damaging, and these variants were assessed for further evidence of disease causation (Tables S2 through S7 in the Supplementary Appendix). Of these, predicted loss-of-function variants in two genes (HAAO, encoding 3-hydroxyanthranilic acid 3,4-dioxygenase, and KYNU, encoding kynureninase) were identified in three consanguineous families and were prioritized for further analysis. HAAO and KYNU are enzymes of the kynurenine pathway and are involved in the synthesis of nicotinamide adenine dinucleotide (NAD) (Fig. 2) . Pathogenic variants in genes that are associated with NAD synthesis were not identified in the remaining 10 families. Neither HAAO nor KYNU has been associated with congenital malformation; however, a KYNU missense mutation (p.T198A) has been reported to be associated with hydroxykynureninuria (Online Mendelian Inheritance in Man [OMIM] number, 236800). 14 Sanger sequencing confirmed variant segregation with disease ( Fig. 1, and Fig. S2 in the Supplementary Appendix). In Family A, the patient was homozygous for a c.483dupT variant in HAAO (ClinVar accession number, SCV000540919), leading to a stop codon (p.D162*). In Family B, the patient was homozygous for a c.558G→A variant in HAAO (ClinVar accession number, SCV000540920), leading to a stop codon (p.W186*). In Family C, the patient was homozygous for a c.170-1G→T splicing variant in KYNU (ClinVar accession number, SCV000540921), leading to a stop codon downstream (p.V57Efs*21). In all three families, the unaffected parents and siblings were either heterozygous for the mutation NAD Deficiency and Congenital Malformations or homozygous for the reference allele, indicating a recessive inheritance pattern. In Family D, the patient was compound heterozygous for KYNU variants c.468T→A (ClinVar accession number, SCV000540922) and c.1045_1051delTTTAAGC (ClinVar accession number, SCV000540923), which were inherited from the father and mother, respectively; each variant results in a stop codon (p.Y156* and p.F349Kfs*4, respectively). The locations of the variants in HAAO and KYNU and their corresponding protein variants are shown in Figure S3 in the Supplementary Appendix.
In Vitro Activity of Mutant HAAO and KYNU
We tested the activity of the truncated enzymes. For HAAO, we quantified the conversion of 3-hydroxyanthranilic acid (3HAA) to 2-amino-3-carboxymuconate-6-semialdehyde (ACMS). For KYNU, we quantified the conversion of 3-hydroxykynurenine (3HK) to 3HAA. (The enzyme assays are described in the Supplementary Appendix.) We tested the identified HAAO and KYNU variant proteins as well as KYNU p.T198A, which is associated with hydroxykynureninuria but not congenital malformation. 14 The specific activity of all the truncated HAAO and KYNU enzymes was 0 to 19% as high as the activity of nonmutant enzymes ( Fig. S4 and Table S8 in the Supplementary Appendix). By contrast, the activity of KYNU p.T198A was 64% as high as the activity of the nonmutant enzyme.
Levels of Metabolites in the Kynurenine Pathway and NAD Levels
We predicted that loss of HAAO or KYNU activity would lead to increased plasma levels of metabolites upstream of these enzymes and reduced levels downstream. Patients A and B (homozygous HAAO stop codon) had upstream 3HAA levels that were 64 and 385 times the levels in unaffected heterozygous family members, respectively. Downstream of HAAO, levels of NAD+ (the oxidized form of NAD) and of NAD(H) (the sum of NAD+ and NADH, the reduced form of NAD) were one third to one quarter of the levels in unaffected heterozygous family members (Tables 1 and 2, and Table S9 in the Supplementary Appendix). Plasma was not available from Family C. Patient D (compound heterozygous for KYNU truncating mutations) had an upstream 3HK level that was 161 times the level in unaffected family members and a downstream NAD(H) T
Modeling of Disease in Mice Null for Haao or Kynu
We generated mice with a null allele for Haao or Kynu (Fig. S5 in the Supplementary Appendix).
Enzyme assays confirmed that the edited alleles were null (Fig. S6 in the Supplementary Appendix). Intercrosses of mice that were heterozygous null for Haao or for Kynu produced embryos in the expected mendelian ratio of genotypes. Unexpectedly, all the embryos were normal (Tables S10 and S11 in the Supplementary Appendix).
We next quantified metabolites upstream and downstream of Haao and of Kynu in adult mouse serum. Haao −/− mice had 3HAA levels that were more than 100 times the levels in Haao +/− mice and wild-type mice (Table S12 in the Supplementary Appendix). Similarly, Kynu −/− mice had 3HK levels that were more than 70 times the levels in Kynu +/− mice and wild-type mice, a metabolic finding consistent with our findings in humans (Tables 1 and 2, and Table S9 in the Supplementary Appendix). By contrast, NAD(H) levels were similar in all the mice, regardless of genotype (Table S12 in the Supplementary Appendix). This suggested that elevated levels of metabolites upstream of HAAO or KYNU in humans did not cause congenital malformation and underscored a deficit in the NAD level as the cause.
NAD is produced by two pathways: one requires dietary tryptophan, and the other requires dietary niacin (Fig. 2) . The NAD de novo synthesis pathway catabolizes tryptophan through the kynurenine pathway, and the NAD salvage pathway converts niacin and other precursors into NAD (independent of KYNU and HAAO). The niacin status of mice as measured by the concentration of NAD in whole blood is at least four times that in humans, possibly because mice convert tryptophan to NAD more efficiently, 15 and they consume more tryptophan or niacin per unit of body weight owing to a higher basal metabolic rate. 16 In mice, reduced niacin status occurs only when both de novo synthesis of NAD is blocked and niacin is removed from the diet. 17 During development, embryos receive niacin from the mother and generate their own. It is therefore possible that maternal niacin has a buffering effect and protects the null mouse embryos from the development of NAD deficiency. We therefore sought to reduce niacin levels in pregnant mice that were heterozygous for a null allele (Haao +/− or Kynu +/− ). As a first attempt to mimic the reduced NAD levels in humans, these mice were fed a niacin-free diet during pregnancy. In litters from Haao +/− or Kynu +/− intercrosses, embryos had the expected mendelian ratio of genotypes and were phenotypically normal (Tables S11 and S13 in the Supplementary Appendix). This observation suggested that het-
Figure 2. Synthesis of Nicotinamide Adenine Dinucleotide (NAD).
NAD is synthesized de novo from the essential amino acid L-tryptophan and salvaged from nicotinamide. Tryptophan and niacin (vitamin B 3 ), which is supplied as nicotinic acid and nicotinamide, represent dietary inputs. Details on NAD synthesis are provided in Figure S1 in the Supplementary Appendix. To preclude maternal NAD production from the de novo synthesis pathway in addition to the salvage pathway, null female mice (Haao −/− or Kynu −/− ) were mated with Haao +/− or Kynu +/− male mice and fed a niacin-free diet. All the embryos died, regardless of genotype (Tables S11 and S14 in the Supplementary Appendix). Death also occurred when the niacin-free diet was limited from embryonic day 0.5 to embryonic day 4.5, 5.5, or 6.5 (Tables S11 and S14 in the Supplementary Appendix). We determined that a niacinfree diet supplemented with 5 mg of nicotinic acid per liter of drinking water between embryonic day 7.5 and embryonic day 12.5 better sustained embryogenesis in null mothers. Despite a large number of resorptions, live null embryos were present (Tables S11 and S15 in the Supplementary Appendix). All the Haao +/− and Kynu +/− embryos were normal. By contrast, all the Haao −/− and Kynu −/− embryos had multiple defects, including defects in vertebral segmentation, heart defects, small kidney, cleft palate, talipes, syndactyly, and caudal agenesis (Fig. S7 and Tables S15 and S16 in the Supplementary Appendix). NAD levels in null mouse embryos were one half the levels in unaffected heterozygous littermates at embryonic day 9.5 ( Fig. 3) . This observation indicates that in both mice and humans, loss of embryonic NAD leads to embryo defects and death. It is the embryonic NAD deficit that causes defects rather than the maternal deficit, because null mothers produce normal heterozygous embryos (Table S15 and Fig. S7 in the Supplementary Appendix).
NAD De Novo Synthesis Pathway
L-tryptophan (diet)
N-Formylkynurenine
To prove that NAD deficiency was disrupting embryogenesis, pregnant null mice were fed a niacin-free diet as before, and water was supplemented with 10 or 15 mg of nicotinic acid per liter. Because mice consume 1.3 liters of water per kilogram of food, 18 we calculated that with this regimen mice would consume 14% of the niacin equivalent in complete mouse chow (90 mg per kilogram). Litters from these mice contained embryos with genotypes in the expected mendelian ratio. With 10 mg of nicotinic acid per liter, null embryos were normal except for kidneys that were 30% smaller than those in heterozygous controls; with 15 mg of nicotinic acid per liter, all the embryos were normal (Table S15 in the Supplementary Appendix). We also observed a dose-dependent increase in embryonic NAD(H) levels in response to maternal niacin supplementation (Fig. 3) , a finding consistent with the ab- Table S9 in the Supplementary Appendix. Plasma was not available from Family C.
Table 2. Alteration in Levels of Metabolites in the Kynurenine Pathway and in NAD Levels in Plasma from Patient B (Family Member II.4).*
T h e ne w e ngl a nd jou r na l o f m e dicine sence of a phenotype. These data show that embryo death and defects were specifically due to a deficit of NAD in embryos and that niacin supplementation prevented the disruption of embryogenesis.
Discussion
We identified mutations blocking de novo NAD synthesis that cause multiple congenital malformations, including those found in the VACTERL association. The NAD de novo synthesis pathway catabolizes tryptophan, leading to the production of NAD. Although metabolite levels upstream of the block are elevated and the metabolites have postnatal functions, 19 we found that it is the deficiency in embryonic NAD, downstream of the block, that is disrupting embryogenesis. We found that in mice, supplementing dietary niacin during gestation prevents embryo defects caused by NAD deficiency. We evaluated the pathogenicity of the HAAO and KYNU variants according to American College of Medical Genetics and Genomics guidelines. 20 On the basis of the predicted deleterious effects that were confirmed by in vitro enzyme assays, an absence or extremely low frequency of minor alleles, and the recessive inheritance pattern, we conclude that all the HAAO and KYNU variants that were identified in this study are pathogenic (Table S17 in the Supplementary Appendix).
NAD deficiency is linked to disease through genetic and environmental means. Severe niacin deficiency causes pellagra, characterized by dermatitis, diarrhea, dementia, and death. 21 Although pellagra is rare today, niacin deficiency that is caused by dietary inadequacies, malabsorption of nutrients, and drug interference is still observed. 21 Moreover, niacin deficiency is common during pregnancy. 22 Niacin deficiency can also be inherited. Hartnup disease, characterized by dermatitis and neurologic and behavioral defects, is caused by mutation of SLC6A19, which is required for the transport of neutral amino acids, including tryptophan. 23 NAD synthesis is also reduced by pathophysiological factors such as type 2 diabetes, obesity, and inflammation. 22, [24] [25] [26] These may have been confounding factors in Families B, C, and D.
Our findings increase understanding of the genetic and environmental causes of congenital malformation. Our discovery that the genetic disruption of NAD synthesis causes congenital malformations suggests that mutation of many genes might have the same effect (Fig. S1 in the Supplementary Appendix). These include genes required for de novo synthesis of NAD, such as genes encoding tryptophan transporters (SLC7A5, SLC7A8, and SLC6A19), genes encoding enzymes of the kynurenine pathway (TDO2, IDO1-2, AFMID, KMO, KYNU, and HAAO), and genes encoding enzymes that convert quinolinic acid to NAD Female mice that were homozygous null for Haao or Kynu were mated with heterozygous male mice. Pregnant mice were fed a niacin-free diet supplemented with 5, 10, or 15 mg of nicotinic acid per liter of drinking water from embryonic day 7.5 to 9.5. Embryos were harvested at embryonic day 9.5, and levels of NAD(H) (the sum of NAD+ and NADH) were quantified. The difference between groups was tested with the use of a one-way analysisof-variance test based on log 2 -transformed data, followed by Dunnett's multiple-comparison test (all other groups vs. null mice receiving 5 mg of nicotinic acid per liter). The middle lines of the I bars indicate mean values, and the I bars ±1 SD. NMNAT1-3, and NADSYN1) . Furthermore, genes encoding enzymes of the NAD salvage pathway (NAMPT and NMNAT1-3) and genes required for the transport of nicotinic acid (SLC5A8 and SLC22A13) or the uptake of dietary niacin (nicotinic acid, nicotinamide, or nicotinamide riboside) or its entry into NAD-producing pathways (NAPRT, PNP, and NMRK1,2) could also be candidates for causing congenital malformations. It is noteworthy that mutation of NMNAT1 causes the retinal degenerative condition Leber's congenital amaurosis type 9 (OMIM number, 608553). Here, the almost-normal enzymatic activity of mutant proteins would preclude a broad phenotype such as congenital malformation. 27 NAD is a cofactor with broad cellular effects that is involved in ATP production, macromolecular synthesis, PARP-dependent DNA repair, and sirtuin-dependent protein deacetylation. 28 NAD+ or NADH participates in approximately 400 redox reactions, NADP+ or NADPH participates in approximately 30 redox reactions, and NAD+ is consumed in approximately 50 reactions involving PARP-dependent DNA repair or sirtuindependent deacetylation. 28 Given the various roles of NAD, there are many possible ways by which a deficit of it might disrupt embryogenesis.
First, NAD is central to energy metabolism, serving as an essential coenzyme in glycolysis, the tricarboxylic acid cycle, and the mitochondrial electron transport chain, and is also central to the production of macromolecules, including nucleotides. Embryogenesis is characterized by dynamic, well-orchestrated cellular proliferation and differentiation. NAD deficiency is therefore likely to most affect tissues undergoing the greatest change.
Second, NAD levels regulate sirtuin-mediated deacetylation, which modulates transcription factors and metabolic enzymes that promote mitochondrial oxidative function and enhance cell survival under stress conditions. [29] [30] [31] Sirtuin activity is required during embryogenesis and affects the fate of stem cells and progenitor cells; loss of activity causes multiple organ defects. 32 Third, DNA repair is active during rodent embryogenesis and is required for normal development. 33 There is evidence that NAD deficiency impairs DNA repair 28 and that a DNA fragmentation disorder in humans, Fanconi's anemia, can result in multiple congenital malformations defining the VACTERL association. 3 In the patients we describe here, there was consistency in the tissues affected but variability in phenotype. Given the phenotypic spectrum and the essential role of NAD, it is possible that additional variable phenotypes may yet be discovered. Such variability is probably due to a range of factors, including gene modifiers in both the mother and the affected child; maternal physiology that is influenced, for example, by diabetes; diet, including the intake of niacin and tryptophan; and other factors affecting NAD production, salvage, and consumption. We theorize that supplementation with high-dose niacin (140 mg per day, which is 10 times the U.S. recommended daily allowance for women) before and during pregnancy might prevent recurrence of disease in these four families. It is also possible that niacin supplementation may benefit the speech and developmental delays in the surviving patients.
In conclusion, many genetic and environmental factors have the potential to cause NAD deficiency during gestation. We propose that cases of congenital malformation that occur because of a deficit in NAD be collectively referred to as congenital NAD deficiency disorders.
